



# Drug Therapy Protocols: Ropivacaine

<b>Policy code</b>	DTP_ROP_0924
<b>Date</b>	September, 2024
<b>Purpose</b>	To ensure a consistent procedural approach to ropivacaine administration.
<b>Scope</b>	Applies to Queensland Ambulance Service (QAS) clinical staff.
<b>Health care setting</b>	Pre-hospital assessment and treatment.
<b>Population</b>	Applies to all ages unless stated otherwise.
<b>Source of funding</b>	Internal – 100%
<b>Author</b>	Clinical Quality & Patient Safety Unit, QAS
<b>Review date</b>	September, 2026
<b>Information security</b>	UNCLASSIFIED – Queensland Government Information Security Classification Framework.
<b>URL</b>	<a href="https://ambulance.qld.gov.au/clinical.html">https://ambulance.qld.gov.au/clinical.html</a>

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: [Clinical.Guidelines@ambulance.qld.gov.au](mailto:Clinical.Guidelines@ambulance.qld.gov.au)

## Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by appropriately qualified QAS clinicians when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

© State of Queensland (Queensland Ambulance Service) 2024.



This work is licensed under the **Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License**

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>

For copyright permissions beyond the scope of this license please contact: [Clinical.Guidelines@ambulance.qld.gov.au](mailto:Clinical.Guidelines@ambulance.qld.gov.au)

# Ropivacaine

September, 2024

## Drug class

Anaesthetics

## Pharmacology

Reversibly interrupts impulse conduction in peripheral nerves and stabilises excitable cell membranes by blocking sodium channels, therefore inhibiting depolarisation.

## Metabolism

Ropivacaine undergoes extensive metabolism, primarily via CYP1A2-mediated aromatic hydroxylation to 3-OH-ropivacaine.

## Schedule

- S4 (Restricted drugs).

### Special notes

- Only credentialed QAS Flight paramedics are authorised to carry medications from the designated LifeFlight medication formulary.
- LifeFlight is responsible for the procurement of all medications in the LifeFlight response kits.

### Indications



- As per LifeFlight standard operating procedure (SOP)

### Contraindications



- Amide local anaesthetic hypersensitivity
- Uncorrected hypotension
- Local inflammation
- Septicaemia
- Bier's block
- Obstetrics paracervical block

## Adult/Paediatric dosages

### As per LifeFlight standard operating procedures (SOP)

ACFP

CCFP

May only be administered on the authority of a LifeFlight Retrieval Medical Officer whilst under direct supervision.